{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:46:54Z","timestamp":1768265214092,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>\n                           <jats:italic>Summary<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>The annual number of patients treated for osteoporosis between 1998 and 2018 in Switzerland increased until 2008 and steadily decreased thereafter. With a continuously growing population at fracture risk exceeding an intervention threshold, the treatment gap has increased and the incidence of hip fractures has stopped declining in the past decade.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>\n                           <jats:italic>Introduction<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>The existence of an osteoporosis treatment gap, defined as the percentage of patients at risk for osteoporotic fractures exceeding an intervention threshold but remaining untreated, is widely acknowledged. Between 1998 and 2018, new bone active substances (BAS) indicated for the treatment of osteoporosis became available. Whether and if so to what extent these new introductions have altered the treatment gap is unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>\n                           <jats:italic>Methods<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>The annual number of patients treated with a BAS was calculated starting from single-drug unit sales. The number of patients theoretically eligible for treatment with a BAS was estimated based on four scenarios corresponding to different intervention thresholds (one based solely on a bone mineral density <jats:italic>T<\/jats:italic> score threshold and three FRAX-based thresholds) and the resulting annual treatment gaps were calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>\n                           <jats:italic>Results<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>In Switzerland, the estimated number of patients on treatment with a BAS increased from 35,901 in year 1998 to 233,381 in year 2018. However, this number grew regularly since 1998, peaked in 2008, and steadily decreased thereafter, in timely coincidence with the launch of intravenous bisphosphonates and the RANKL inhibitor denosumab. When expressed in numbers of untreated persons at risk for osteoporotic fractures exceeding a given intervention threshold, the treatment gaps were of similar magnitude in 1998 (when the first BSAs just had become available) and 2018. There was a strong association, which does not imply causation, between the proportion of patients treated and hip fracture incidence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>\n                           <jats:italic>Conclusion<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>In Switzerland, the osteoporosis treatment gap has increased over the past decade. The availability of new BAS has not contributed to its decrease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11657-022-01206-6","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:05:49Z","timestamp":1674000349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The osteoporosis treatment gap in Switzerland between 1998 and 2018"],"prefix":"10.1007","volume":"18","author":[{"given":"Kurt","family":"Lippuner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita Yousefi","family":"Moghadam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"1206_CR1","unstructured":"(1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1\u2013129"},{"key":"1206_CR2","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00198-008-0779-8","volume":"20","author":"K Lippuner","year":"2009","unstructured":"Lippuner K, Johansson H, Kanis JA, Rizzoli R (2009) Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int 20:1131\u20131140","journal-title":"Osteoporos Int"},{"issue":"11","key":"1206_CR3","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s00198-022-06481-0","volume":"33","author":"K Lippuner","year":"2022","unstructured":"Lippuner K, Rimmer G, Stuck AK, Schwab P, Bock O (2022) Hospitalizations for major osteoporotic fractures in Switzerland: a long-term trend analysis between 1998 and 2018. Osteoporos Int 33(11):2327\u20132335","journal-title":"Osteoporos Int"},{"key":"1206_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"1206_CR5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"1206_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"1206_CR7","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00198-021-05890-x","volume":"32","author":"MK Skjodt","year":"2021","unstructured":"Skjodt MK, Ernst MT, Khalid S et al (2021) The treatment gap after major osteoporotic fractures in Denmark 2005\u20132014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications. Osteoporos Int 32:1961\u20131971","journal-title":"Osteoporos Int"},{"key":"1206_CR8","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00198-017-4072-6","volume":"28","author":"A Keshishian","year":"2017","unstructured":"Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O (2017) Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population. Osteoporos Int 28:2485\u20132494","journal-title":"Osteoporos Int"},{"key":"1206_CR9","doi-asserted-by":"publisher","first-page":"115071","DOI":"10.1016\/j.bone.2019.115071","volume":"142","author":"O Malle","year":"2021","unstructured":"Malle O, Borgstroem F, Fahrleitner-Pammer A, Svedbom A, Dimai SV, Dimai HP (2021) Mind the gap: incidence of osteoporosis treatment after an osteoporotic fracture - results of the Austrian branch of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS). Bone 142:115071","journal-title":"Bone"},{"key":"1206_CR10","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00198-020-05339-7","volume":"31","author":"L Iconaru","year":"2020","unstructured":"Iconaru L, Smeys C, Baleanu F et al (2020) Osteoporosis treatment gap in a prospective cohort of volunteer women. Osteoporos Int 31:1377\u20131382","journal-title":"Osteoporos Int"},{"key":"1206_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgstrom F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82","journal-title":"Arch Osteoporos"},{"key":"1206_CR12","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1007\/s00198-021-05951-1","volume":"32","author":"AJ Singer","year":"2021","unstructured":"Singer AJ, Liu J, Yan H, Stad RK, Gandra SR, Yehoshua A (2021) Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage. Osteoporos Int 32:2473\u20132484","journal-title":"Osteoporos Int"},{"key":"1206_CR13","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","volume":"29","author":"NC Wright","year":"2014","unstructured":"Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29:2520\u20132526","journal-title":"J Bone Miner Res"},{"key":"1206_CR14","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s00198-011-1869-6","volume":"23","author":"K Lippuner","year":"2012","unstructured":"Lippuner K, Johansson H, Borgstrom F, Kanis JA, Rizzoli R (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX(R) in Switzerland. Osteoporos Int 23:2579\u20132589","journal-title":"Osteoporos Int"},{"key":"1206_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00198-009-0975-1","volume":"21","author":"K Lippuner","year":"2010","unstructured":"Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381\u2013389","journal-title":"Osteoporos Int"},{"key":"1206_CR16","doi-asserted-by":"publisher","first-page":"w20352","DOI":"10.4414\/smw.2020.20352","volume":"150","author":"S Ferrari","year":"2020","unstructured":"Ferrari S, Lippuner K, Lamy O, Meier C (2020) 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss Med Wkly 150:w20352","journal-title":"Swiss Med Wkly"},{"key":"1206_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11657-014-0187-y","volume":"9","author":"A Svedbom","year":"2014","unstructured":"Svedbom A, Ivergard M, Hernlund E, Rizzoli R, Kanis JA (2014) Epidemiology and economic burden of osteoporosis in Switzerland. Arch Osteoporos 9:187","journal-title":"Arch Osteoporos"},{"key":"1206_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11657-022-01117-6","volume":"17","author":"P Chotiyarnwong","year":"2022","unstructured":"Chotiyarnwong P, McCloskey EV, Harvey NC et al (2022) Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology\/Quality of Life Working Group. Arch Osteoporos 17:87","journal-title":"Arch Osteoporos"},{"key":"1206_CR19","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s00198-021-05917-3","volume":"32","author":"NC Harvey","year":"2021","unstructured":"Harvey NC, Kanis JA, Liu E, Vandenput L, Lorentzon M, Cooper C, McCloskey E, Johansson H (2021) Impact of population-based or targeted BMD interventions on fracture incidence. Osteoporos Int 32:1973\u20131979","journal-title":"Osteoporos Int"},{"key":"1206_CR20","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00198-020-05507-9","volume":"31","author":"G Koller","year":"2020","unstructured":"Koller G, Goetz V, Vandermeer B, Homik J, McAlister FA, Kendler D, Ye C (2020) Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int 31:2093\u20132102","journal-title":"Osteoporos Int"},{"key":"1206_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11657-016-0282-3","volume":"11","author":"E Tremblay","year":"2016","unstructured":"Tremblay E, Perreault S, Dorais M (2016) Persistence with denosumab and zoledronic acid among older women: a population-based cohort study. Arch Osteoporos 11:30","journal-title":"Arch Osteoporos"},{"key":"1206_CR22","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00198-019-04963-2","volume":"30","author":"DM Borek","year":"2019","unstructured":"Borek DM, Smith RC, Gruber CN, Gruber BL (2019) Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study. Osteoporos Int 30:1455\u20131464","journal-title":"Osteoporos Int"},{"key":"1206_CR23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","volume":"18","author":"JA Cramer","year":"2007","unstructured":"Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023\u20131031","journal-title":"Osteoporos Int"},{"key":"1206_CR24","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMp1202619","volume":"366","author":"M Whitaker","year":"2012","unstructured":"Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis\u2013where do we go from here? N Engl J Med 366:2048\u20132051","journal-title":"N Engl J Med"},{"key":"1206_CR25","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1185\/030079904125004475","volume":"20","author":"G Rodan","year":"2004","unstructured":"Rodan G, Reszka A, Golub E, Rizzoli R (2004) Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20:1291\u20131300","journal-title":"Curr Med Res Opin"},{"key":"1206_CR26","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"1206_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","volume":"19","author":"NB Watts","year":"2008","unstructured":"Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365\u2013372","journal-title":"Osteoporos Int"},{"key":"1206_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243\u2013254","journal-title":"J Bone Miner Res"},{"key":"1206_CR29","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","volume":"362","author":"DM Black","year":"2010","unstructured":"Black DM, Kelly MP, Genant HK et al (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761\u20131771","journal-title":"N Engl J Med"},{"key":"1206_CR30","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"1206_CR31","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00198-016-3894-y","volume":"28","author":"NC Harvey","year":"2017","unstructured":"Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28:1507\u20131529","journal-title":"Osteoporos Int"},{"key":"1206_CR32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jval.2010.11.010","volume":"14","author":"S Ross","year":"2011","unstructured":"Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14:571\u2013581","journal-title":"Value Health"},{"key":"1206_CR33","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","volume":"21","author":"I Imaz","year":"2010","unstructured":"Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943\u20131951","journal-title":"Osteoporos Int"},{"key":"1206_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial. JAMA 288:321\u2013333","journal-title":"JAMA"},{"key":"1206_CR35","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"GL Anderson","year":"2004","unstructured":"Anderson GL, Limacher M, Assaf AR et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial. JAMA 291:1701\u20131712","journal-title":"JAMA"},{"key":"1206_CR36","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/pds.5186","volume":"30","author":"M Heinig","year":"2021","unstructured":"Heinig M, Braitmaier M, Haug U (2021) Prescribing of menopausal hormone therapy in Germany: current status and changes between 2004 and 2016. Pharmacoepidemiol Drug Saf 30:462\u2013471","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1206_CR37","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/GME.0000000000001282","volume":"26","author":"SL Crawford","year":"2018","unstructured":"Crawford SL, Crandall CJ, Derby CA, El Khoudary SR, Waetjen LE, Fischer M, Joffe H (2018) Menopausal hormone therapy trends before versus after 2002: impact of the Women\u2019s Health Initiative Study Results. Menopause 26:588\u2013597","journal-title":"Menopause"},{"key":"1206_CR38","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jama.299.9.1036","volume":"299","author":"G Heiss","year":"2008","unstructured":"Heiss G, Wallace R, Anderson GL et al (2008) Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299:1036\u20131045","journal-title":"JAMA"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-022-01206-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-022-01206-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-022-01206-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T13:23:51Z","timestamp":1704374631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-022-01206-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1206"],"URL":"https:\/\/doi.org\/10.1007\/s11657-022-01206-6","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"25 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is not required by Swiss law for database analyses without individual patient data","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None was declared by BYM and PS. KL has served as an expert in advisory board meetings of Amgen Switzerland AG and UCB Pharma AG Switzerland.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"20"}}